BAM
REGN icon

Belpointe Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Belpointe Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
2,371
+158
+7% +$108K 0.05% 369
2026
Q1 		$1.71M Sell
2,213
-35
-2% -$26.8K 0.06% 280
2025
Q4 		$1.74M Buy
+2,248
New +$1.53M 0.06% 251
2025
Q2 		– Sell
-1,011
Closed -$641K – 1010
2025
Q1 		$641K Sell
1,011
-959
-49% -$660K 0.03% 480
2024
Q4 		$2.34M Buy
1,970
+127
+7% +$107K 0.14% 148
2024
Q3 		$1.94M Buy
1,843
+54
+3% +$60.1K 0.12% 177
2024
Q2 		$1.88M Buy
1,789
+475
+36% +$460K 0.13% 149
2024
Q1 		$1.26M Buy
1,314
+985
+299% +$937K 0.09% 210
2023
Q4 		$289K Sell
329
-483
-59% -$398K 0.03% 535
2023
Q3 		$668K Buy
812
+439
+118% +$345K 0.07% 268
2023
Q2 		$268K Sell
373
-669
-64% -$516K 0.03% 498
2023
Q1 		$856K Sell
1,042
-61
-6% -$46K 0.05% 376
2022
Q4 		$796K Sell
1,103
-150
-12% -$111K 0.05% 384
2022
Q3 		$863K Buy
1,253
+604
+93% +$380K 0.06% 337
2022
Q2 		$384K Sell
649
-4
-0.6% -$2.6K 0.03% 592
2022
Q1 		$456K Sell
653
-1,122
-63% -$710K 0.03% 566
2021
Q4 		$1.12M Sell
1,775
-3,525
-67% -$2.17M 0.07% 287
2021
Q3 		$3.21M Buy
5,300
+2,842
+116% +$1.76M 0.22% 93
2021
Q2 		$1.37M Sell
2,458
-2,043
-45% -$1.04M 0.1% 225
2021
Q1 		$1.93M Buy
4,501
+4,080
+969% +$1.99M 0.17% 135
2020
Q4 		$203K Buy
421
+2
+0.5% +$1.08K 0.02% 687
2020
Q3 		$235K Sell
419
-624
-60% -$378K 0.03% 511
2020
Q2 		$650K Sell
1,043
-15
-1% -$8.51K 0.08% 246
2020
Q1 		$517K Sell
1,058
-486
-31% -$200K 0.09% 238
2019
Q4 		$580K Buy
+1,544
New +$519K 0.07% 294

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Belpointe Asset Management's REGN Position: Q2 2026 in Review

Belpointe Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 7.1% in Q2 2026, buying an estimated $108K and bringing the position to 2,371 shares worth $1.48M. The position accounts for 0.05% of the portfolio, ranked #369.

Belpointe Asset Management first reported a position in REGN in Q4 2019 and has held it in 25 quarters since. The position peaked at $3.21M in Q3 2021. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Belpointe Asset Management held 2,371 shares of Regeneron Pharmaceuticals worth $1.48M as of Q2 2026.
  • Belpointe Asset Management bought 158 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $108K.
  • Regeneron Pharmaceuticals made up 0.05% of Belpointe Asset Management's portfolio in Q2 2026, its #369 holding.
  • Belpointe Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • Belpointe Asset Management's Regeneron Pharmaceuticals position peaked at $3.21M in Q3 2021.
  • 518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.